Copied
 
 
2022, DKK
16.05.2024
Bruttoresultat

154''

Primær drift

28.402'

Årets resultat

29.279'

Aktiver

555''

Kortfristede aktiver

269''

Egenkapital

317''

Afkastningsgrad

5 %

Soliditetsgrad

57 %

Likviditetsgrad

113 %

Resultat
16.05.2024
Årsrapport
2022
16.05.2024
2021
28.04.2023
2020
11.01.2022
2019
11.01.2021
2018
31.03.2020
2017
30.04.2019
2016
28.03.2018
2015
31.03.2017
Nettoomsætning932.011.000929.787.000909.643.000808.132.000997.951.000746.062.000847.330.000
Bruttoresultat153.999.000150.748.000185.823.000171.775.000237.575.000233.194.000142.580.000136.435.000
Resultat af primær drift28.402.00037.169.00060.982.00027.864.00086.421.000101.384.00022.198.00018.229.000
Indtægter af kapitalandele (tilknyttede og associerede) 00000000
Finansielle indtægter3.635.0001.528.0009.929.0009.609.00010.797.00020.106.00013.500.00020.988.000
Finansieringsomkostninger-14.906.000-31.475.000-3.536.000-657.000-445.000-4.267.000-2.330.000-1.365.000
Andre finansielle omkostninger00000-4.267.000-2.330.000-1.365.000
Resultat før skat38.294.00012.408.00051.375.00015.100.00096.773.00084.023.00033.368.00037.852.000
Resultat29.279.000-111.707.00036.973.0007.202.00084.904.00074.638.00034.342.00044.402.000
Forslag til udbytte-95.000.0000-30.000.000-100.000.0000-130.000.00000
Aktiver
16.05.2024
Årsrapport
2022
16.05.2024
2021
28.04.2023
2020
11.01.2022
2019
11.01.2021
2018
31.03.2020
2017
30.04.2019
2016
28.03.2018
2015
31.03.2017
Kortfristede varebeholdninger0017.193.00030.849.00047.100.000153.554.000175.690.00087.500.000
Kortfristede tilgodehavender fra salg og tjenesteydelser 244.262.000238.558.000227.498.000259.735.000285.800.000195.325.000175.755.00041.936.000
Likvider24.519.00086.642.00024.516.00043.145.00027.275.00012.791.000017.606.000
Kortfristede aktiver268.781.000325.200.000269.207.000333.729.000360.175.000361.670.000351.445.000147.042.000
Immaterielle aktiver og goodwill2.058.0004.054.0001.889.0003.029.0003.658.00087.770.000107.743.000115.622.000
Finansielle anlægsaktiver283.302.000184.561.000198.799.000261.519.000239.789.000211.689.000251.588.000240.106.000
Materielle aktiver428.000764.00056.330.00068.054.00078.023.00081.906.00085.469.00086.241.000
Langfristede aktiver285.788.000189.379.000257.018.000332.602.000321.470.000381.365.000444.800.000441.969.000
Aktiver554.569.000514.579.000526.225.000666.331.000681.645.000743.035.000796.245.000589.011.000
Aktiver
16.05.2024
Passiver
16.05.2024
Årsrapport
2022
16.05.2024
2021
28.04.2023
2020
11.01.2022
2019
11.01.2021
2018
31.03.2020
2017
30.04.2019
2016
28.03.2018
2015
31.03.2017
Forslag til udbytte95.000.000030.000.000100.000.0000130.000.00000
Egenkapital316.817.000287.538.000429.245.000502.520.000495.318.000540.415.000465.777.000438.225.000
Hensatte forpligtelser00000000
Langfristet gæld til banker00000000
Anden langfristet gæld0000959.000712.0001.870.000
Leverandører af varer og tjenesteydelser9.602.0007.433.00013.913.00015.890.00017.621.00029.561.00039.001.00017.036.000
Kortfristede forpligtelser237.752.000227.041.00096.980.000163.811.000186.327.000165.098.000329.756.000148.916.000
Gældsforpligtelser237.752.000227.041.00096.980.000163.811.000186.327.000202.620.000329.756.000150.786.000
Forpligtelser237.752.000227.041.00096.980.000163.811.000186.327.000202.620.000329.756.000150.786.000
Passiver554.569.000514.579.000526.225.000666.331.000681.645.000743.035.000796.245.000589.011.000
Passiver
16.05.2024
Nøgletal
16.05.2024
Årsrapport
2022
16.05.2024
2021
28.04.2023
2020
11.01.2022
2019
11.01.2021
2018
31.03.2020
2017
30.04.2019
2016
28.03.2018
2015
31.03.2017
Afkastningsgrad 5,1 %7,2 %11,6 %4,2 %12,7 %13,6 %2,8 %3,1 %
Dækningsgrad 16,5 %16,2 %20,4 %21,3 %23,8 %31,3 %16,8 %Na.
Resultatgrad 3,1 %-12,0 %4,1 %0,9 %8,5 %10,0 %4,1 %Na.
Varelagerets omsætningshastighed Na.Na.52,9 26,2 21,2 4,9 4,8 Na.
Egenkapitals-forretning 9,2 %-38,8 %8,6 %1,4 %17,1 %13,8 %7,4 %10,1 %
Payout-ratio 324,5 %Na.81,1 %1.388,5 %Na.174,2 %Na.Na.
Gældsdæknings-nøgletal 190,5 %118,1 %1.724,6 %4.241,1 %19.420,4 %2.376,0 %952,7 %1.335,5 %
Soliditestgrad 57,1 %55,9 %81,6 %75,4 %72,7 %72,7 %58,5 %74,4 %
Likviditetsgrad 113,1 %143,2 %277,6 %203,7 %193,3 %219,1 %106,6 %98,7 %
Resultat
16.05.2024
Gæld
16.05.2024
Årsrapport
16.05.2024
Nyeste:01.11.2022- 31.10.2023(offentliggjort: 16.05.2024)
Information om virksomhedens regnskabsklasse:The annual report for Origio A/S is presented in accordance with those regulations of the Danish Financial Statements Act concerning companies identified as class C enterprises (large enterprises). The accounting policies used are unchanged compared to last year, and the annual accounts are presented in Danish kroner (DKK).
Oplysning om pantsætninger og sikkerhedsstillelser:17. Contractual obligations, contingencies, etc. Contractual obligations The Company has entered into operating leases at the following amounts: The company has entered into a tenancy agreement, of which there are the following tenancy obligations: • Short term: DKK 1.755 thousand • Long term: DKK 8.948 thousand (until 1/9 2029) Joint taxation The company acts as administration company for the group of companies subject to the Danish scheme of joint taxation and is unlimitedly, jointly, and severalle liable, along with the other jointly taxed companies, to pay the total corporation tax. The company is unlimited jointly and severally liable with the other jointly taxed companies for any obligation to withhold tax on interest, royalties and dividends. The liability relating to obligations in connection with withholding tax on dividends, interest, and royalties represents an estimated maximum of DKK 0 thousand. Any subsequent adjustments of corporate taxes or withholding taxes, etc., may cause changes in the company's liabilities.
Beretning
16.05.2024
Dato for ledelsens godkendelse af årsrapporten:2024-05-16
Beskrivelse af usikkerhed ved indregning eller måling:Uncertainties as to recognition or measurement Determining the carrying amounts of certain assets and liabilities requires an estimate of how future events will affect the value of these assets and liabilities at the balance sheet date. Estimates that are material to the financial statements are made regarding measurement of equity investments in group companies and uncertain tax positions. The estimates are based on assumptions that management believes are reasonable but which are inherently uncertain and unpredictable. The assumptions may be incomplete or inaccurate, and unexpected events or circumstances may occur. The Company is also subject to risks and uncertainties that may cause actual results to differ from these estimates. The impairment assessment of investments in group companies are based on expectations of future cash flows of the individual companies. The assessment requires the establishment of assumptions and estimates of future cash flows and discount rate (WACC). The assessment of uncertain tax positions is based on determine whether it is probable that a benefit may be recognized and measure the amount of the benefit based on the probability of different outcomes.
Beskrivelse af usædvanlige forhold, der kan have påvirket indregningen eller målingen:Business review ORIGIO will continue its focus to further grow and strengthening it's strong position in offering best in class products, driving and evolving innovation in line with customer needs. The collaboration within the CooperSurgical Companies and trusted partnerships open doors to extensive possibilities for the future.
Statement by Management on the annual report
Identifikation af den godkendte årsrapport:The supervisory board and the executive board have today discussed and approved the annual report of Origio A/S for the financial year 1 November 2022 - 31 October 2023.
Management's review
Beskrivelse af virksomhedens væsentligste aktiviteter:The principal activities of the company ORIGIO has been part of the CooperSurgical Companies since 2012. CooperSurgical Fertility Solutions is the global leader in IVF (In Vitro Fertilisering) and reproductive genetics, providing innovative products and services for every step in the ART journey (Assisted Reproductive Technology). Our company vision is a world with healthy women, babies and families. ORIGIO A/S was established in 1987 and has been a global leader in delivering innovative ART solu- tions. Combining the scientific knowledge with the CooperSurgical fertility companies ORIGIO, Research Instrument, Safe Obstetrics Systems and Invitro offer a broad range of trusted systems of consumables, equipment, and technologies for a complete IVF process. In 2016 Reprogenetics, Recombine and Genesis Genetics joined the CooperSurgical family, and repre- sented the pioneers and global leaders of comprehensive reproductive genetic testing. As CooperGenomicsSM, they are the premier provider of genetic testing for every step of the family planning journey. Our combined product range includes pipettes, media and andrology products, and dedicated ART equipment, as well as state-of-the art electronic witnessing system. Our broad portfolio of products and services are being developed jointly in partnerships with experts and clinics across the globe to improve the ART solutions. Our industry-leading ART development program includes 7 Centers of Excellence around the world as well as collaboration with our external partners’ training facilities, such as the Centre of Reproductive Medicine at the Vrije Universiteit Brussel in Brussels. We offer a wide range of courses and workshops for embryologists, gynecologists, lab managers and R&D scientists at every level of experience, with hands-on expert training in breakthrough technologies and next-generation techniques. Our team of experienced embryologists also assists customers with the establishment of clinics (turn-key projects), laboratory design, and clinic audits to optimize lab performance. In addition, they give lectures, run seminars and workshops, and support the research and development of new products.
Vi bruger cookies til at øge oplevelsen og målrette vores markedsføring.
Ved at klikke OK tillader du brug af cookies. Læs mere her.
OK